Found 1 result

Search term: MF = 'C_{12}H_{6}N_{2}O_{8}SSr_{2}'
ChemSpider 2D Image | Strontium Ranelate | C12H6N2O8SSr2

Strontium Ranelate

  • Molecular FormulaC12H6N2O8SSr2
  • Average mass513.490 Da
  • Monoisotopic mass513.795715 Da
  • ChemSpider ID5293393

  • Charge - Charge

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

Strontium Ranelate
135459-90-4 [RN]
3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2) [ACD/Index Name]
5-[Bis(carboxylatométhyl)amino]-3-(carboxylatométhyl)-4-cyano-2-thiophènecarboxylate de distrontium [French] [ACD/IUPAC Name]
Distrontium 5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyano-2-thiophenecarboxylate [ACD/IUPAC Name]
Distrontium 5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate
Distrontium renelate
distrontium(2+) 5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyanothiophene-2-carboxylate
Distrontium-5-[bis(carboxylatomethyl)amino]-3-(carboxylatomethyl)-4-cyan-2-thiophencarboxylat [German] [ACD/IUPAC Name]
Osseor [Trade name]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

FK-481 [DBID]
S-12911 [DBID]
  • Miscellaneous

    • Safety:

      M05BX03 Wikidata Q419215

    • Target Organs:

      Calcium Channel inhibitor TargetMol T1641

    • Bio Activity:

      Calcium Channel TargetMol T1641
      CaSR MedChem Express HY-17397
      GPCR/G protein; MedChem Express HY-17397
      Membrane Transporter/Ion Channel TargetMol T1641
      Strontium ranelate(S12911) stimulates the calcium sensing receptors (CaSR) and leads to the differentiation of pre-osteoblast to osteoblast which increases the bone formation. MedChem Express
      Strontium ranelate(S12911) stimulates the calcium sensing receptors (CaSR) and leads to the differentiation of pre-osteoblast to osteoblast which increases the bone formation.;IC50 value:;Target: CaSRStrontium Ranelate is a bone metabolism modulator that inhibits bone resorption while maintaining bone formation. Strontium Ranelate acts by increasing bone formation and decreasing bone resorption, thus rebalancing bone turnover in favour of bone formation, an effect that results in increased bone mass and strength. Commonly used as an antiosteoporotic. Strontium Ranelate has shown efficacy in preventing early postmenopausal bone loss and reducing the risk of hip fracture in women with postmenopausal osteoporosis. MedChem Express HY-17397

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site


Advertisement